Weiguang Biology: The per capita use of blood products in China is currently relatively low.

Wei Guang Biological said at the performance briefing on May 8th that, according to market research institutions, the global blood products industry is expected to continue growing due to factors such as the increasing number of patients, the improvement in the utilization rate of blood products, and the expansion of regional markets. Currently, the per capita utilization of blood products in China is relatively low. In the future, with the improvement of economic and medical levels, as well as the increasingly evident trend of population aging, it is expected that the per capita demand for blood products in China will significantly increase, and the market space will further expand.